

r personal use only

Beamtree

Half Year Investor Presentation

March 2022



Financial Summary 1H FY22

Growth and investment was the focus for the first half of FY22, despite ongoing challenges presented by the COVID-19 pandemic. Thanks to strong revenue performance and excellent customer retention rates, we were able to make significant investments across the business within our budgeted forecast. Our position remains strong as we enter the second half of FY22.

Strong total revenue performance

\$7.1 million

+91% growth in group's revenue and 24% YoY growth exc. acquisitions

Recurring revenue

85%

Exceeded management forecast

Net cash of

\$6.5 million

Position remains strong

ARR (annual recurring revenue)

\$16.8 million

Continued growth YoY

Operational EBITDA loss of

\$0.5 million

Investment in headcount for sales, product and technology capabilities

Customer Renewal

100%

Globally

Beamtree has seen continued growth in the first half of FY22



Key acquisition of Potential^(x) making Beamtree Australia's largest health data and AI decision support platform.

Ai

Key acquisition of Ainsoff to drive AI product innovation.



100% of our retention and renewal goals for the first half of FY22.



94% increase in staff, due to the integration of Potential(x) and Ainsoff. Beamtree also invested in new skills with 20 new technical staff for product development and go to market professionals in 1H FY22.



We have continued to win major contracts and form strategic partnerships with organisations in Australia and internationally. These include Central Adelaide Local Health Network, Ampath (South Africa), and Southern DHB (NZ).

Building our international program – snapshot of progress

New contract wins in four countries. Groundbreaking strategic partnerships to develop new applications in computer-assisted clinical record coding and remote monitoring of patient deterioration

Australia

- Central Adelaide LHN has become the first public hospital to trial implementation of Ainsoff One following clinical trials in Sydney – live trial to start in March
- Queensland Health due to launch Beamtree program in the next month

Europe

- UK – Three major NHS hospital trusts to trial auto coding, Ainsoff One, RippleDown® in pathology
- Italy – discussions around potential application of Ainsoff One for elective waiting list management

Saudi Arabia

- Working with Saudi government and hospitals on a second phase of work to improve ongoing coding of clinical records and the secondary uses of this data

International Diagnostics

- New partnership with Abbott laboratories to significantly expand reach
- Philips launch RippleDown® as integrated CDS in new LIS
- South Africa – Ampath sign for RippleDown®.

AI decision support

- Regional systems and hospital partners plan implementation of breakthrough decision support applications in Hong Kong and USA.

Global Health Comparators

- Seventeen of the world's leading hospitals agree to build on existing collaboration and participate in international benchmarking programme.

Our growth strategy is based on global acceleration in five product and service domains

Beamtree delivers product and services that enable the power of **data, automation** and **people** to **improve health & wellbeing.**




Diagnostic technology

We enable the efficient and effective delivery of the diagnostic services as they underpin the future of health and personalised medicine.



Automation, coding and data integrity:

We digitize and automate workflows with data, classification, coding & technical expertise to improve information availability and quality.



Decision support

We bring artificial and human expertise together to enhance decisions that improve care, value and experience.



Analytics and knowledge networks:

Combining data analytics solutions with peer-to-peer alliances that accelerate innovation and knowledge diffusion.



Professional services:

Digital health advisory and research expertise, providing support in service to our client's success and sustainable impact.

The propositions have attractive fundamentals total market size of ~\$120b in 2026/27

	SCALE & GROWTH	ACHIEVABILITY	STRATEGIC ALIGNMENT	COMPETITION / ENTRY	OVERALL ASSESSMENT
DIAGNOSTIC TECHNOLOGY	<ul style="list-style-type: none"> Est 10% CAGR, ~\$2.9b to 2027 (Diagnostic Support) 	<ul style="list-style-type: none"> High: especially through sound Channel Partner relationships 	High	<ul style="list-style-type: none"> Increasing competition First mover advantage and business model protection 	
AUTOMATION, CODING & DATA INTEGRITY	<ul style="list-style-type: none"> Est 10% CAGR, \$370b to 2026 (BPO, Finance, Coding, Audit) Assume Coding & Data related is ~\$30-\$50b 	<ul style="list-style-type: none"> Medium – lots of players seeking to disrupt High development costs 	High	<ul style="list-style-type: none"> Competition from large players (3M, EMR, BPO) Differentiated IP and solution capability 	
DECISION SUPPORT	<ul style="list-style-type: none"> Est 11% CAGR, ~\$2.2b to 2026 (all Clinical Decision Support) 	<ul style="list-style-type: none"> Medium – highly competitive, high development costs and targeted by disruptive technologies 	High	<ul style="list-style-type: none"> Competition from large players (EMR, Tech) Differentiated IP and solution capability 	
ANALYTICS & KNOWLEDGE NETWORKS	<ul style="list-style-type: none"> Est 25% CAGR, ~\$34b to 2026 	<ul style="list-style-type: none"> Existing capability and expertise Market access 	High	<ul style="list-style-type: none"> Increasing competition First mover advantage and business model protection 	
PROFESSIONAL SERVICES	<ul style="list-style-type: none"> Medium Underpins delivery & ongoing client success 11% CAGR, ~\$27b to 2026 	<ul style="list-style-type: none"> Medium Speed of procurement Low product development, high return / cross sell 	High	<ul style="list-style-type: none"> Highly fragmented market General trend away from 'big brand' Expect growth in data related projects 	

Better Has No Limit: the problems we solve

The best health services deliver value for money by reducing avoidable mortality, waste, length of stay, readmissions and cost of care.

Complications are costly. One in nine patients who go to hospital suffer a complication, which costs Australian hospitals more than A\$5 billion a year.


15 per cent of hospital expenditure in high-income countries is due to human error or patients being adversely affected while in hospital.

Beamtree can help:

- Tackle unwarranted variation
- Address equity of access and resource allocation
- Offer revenue assurance
- Manage risk
- Promote transparency
- Drive automation

How we create value: the Learning Health System

Driving continuous improvement by better access to healthcare information – towards safety, quality and efficiency.



personal use only

Data, insights and action for better healthcare

Our solutions and services help clients make the best use of their data. From improving the quality of the inputs, to better visualising the outputs and automating decisions, we help healthcare providers make informed decisions and improve patient outcomes.



Clinical Coding

Improve quality and accuracy of clinical coding through automation



Analytics & Insights

Turn data into insight through comparative benchmarking and interactive dashboards



Automation & Decision Support

Automate decision-making to transform clinical effectiveness and efficiency




Advisory & Services


Transform insights into action through support, networking, education and research

for personal use only

Beamtree is creating next-generation solutions to enable the learning health system



Highlights of FY22




Media Mentions



New hospital system predicts the future of a patient's condition

Oct 28, 2021

<https://www.9news.com.au/national/new-medical-system-for-hospitals-monitor-patients-warning-signs-new-south-wales/e1b8e92f-3b7b-4171-82f9-612f316dc84c>



Healthcare cloud solutions to watch

Nov 2, 2021

<https://www.afr.com/wealth/personal-finance/healthcare-cloud-solutions-to-watch-20211031-p594sh>

"The beauty of the system is when you look at the single ward say 30 patients you can see instantly if there are any patients who are sick"

Dr Levi Bassin

Key Partnerships and International Expansion

Key Strategic Partnerships

- Strategic partnership with Central Adelaide Local Health Network (CALHN) in South Australia to implement its decision support platform.
- A strategic partnership with Southern DHB in New Zealand to implement proprietary data capture bar coding technology to support quality surveillance of outcomes in allied health.

New Australian Clients

Major new client wins for PICQ® (data quality) and RISQ™ (benchmarking services) in Australian hospitals. These services now assess around 90% of inpatient activity in Australia.

International expansion

- Completion of the national clinical coding quality improvement audit in Kingdom of Saudi Arabia (TCV AUD \$2.25m), working with 73 Ministry of Health sites across the country.
- Completion of a data and analytics discovery project with Johns Hopkins Aramco Healthcare (a joint venture between Saudi Aramco and Johns Hopkins Medicine).
- International growth continues with key contract with leading South African pathology provider Ampath.

Collaborative Partnerships

As part of the acquisition of Potential^(x), Beamtree now provides services to the following organisations.

the ability roundtable

- Established in 2013, Ability Roundtable is a not-for-profit benchmarking and knowledge-sharing organisation in the disability sector.
- Continued service improvements have reduced the data turnaround time by two months and transitioned from PDFs to online analytics. This has resulted in a 30% YOY increase in revenue.



- Established in 1995, Health Roundtable is a not-for-profit benchmarking and knowledge-sharing organisation
- Members include 90% of large (300+ bed) hospitals across every state and territory in Australia, all of New Zealand and the Abu Dhabi Health Authority.
- Independent Board provides oversight & governance.
- Renewals for the Health Roundtable track in line with historical trends, currently sitting at 85% completion for the calendar year of 2022. Recent introduction of multi-year subscriptions for HRT has seen commitments for 2023 and 2024 subscriptions from approximately 20% of Members.

New Products & Enhancements

Growth in microbiology and pathology

RippleDown® Artificial Intelligence (AI) decision support expanded into microbiology and pathology services in several new countries with channel partners Philips and Abbott.

Improvements and enhancements

Major new releases for RippleDown®, PICQ® and RISQ™ have resulted in performance improvements and service enhancements.

Production of hacBI platform

Development and implementation of a new business intelligence platform for Hospital Acquired Complications (HAC's) in partnership with a large private provider.

Wellbeing product suite

The Wellbeing product is largely packaged and delivered through the Health Roundtable partnership, with the Royal Children's Hospital, Melbourne taking up the Beamtree version in late 2021.

Thought Leadership & Collaboratives

Global Impact Committee

Chaired by Mark Britnell, this advisory board includes 15 international healthcare leaders from Australia, Canada, UK, Ireland, USA, Singapore, India, Italy and Sweden. Following the first meeting in October, the committee is working on its first research paper. The paper will consider the major issues facing health systems around the world and put forward solutions that can make a real difference to the quality of care.

International Collaborative

The Global Health Comparators Program empowers hospitals and hospital systems to look beyond their national boundaries to measure performance, explore variation and identify areas for improvement. It has incorporated hospitals from the Global Health Data@Work network from England, Italy, the USA and Belgium and is expected to grow quickly and organically. Initial discussions with hospitals from England, Wales, Italy, and Belgium have been very positive.

Thought Leadership

In partnership with Health Roundtable, industry recognised thought leaders were convened to discuss health staff burnout and offer solutions. The result is a white paper titled *Addressing Burnout. Bringing data-driven solutions, care and hope to the health workforce*, released in December 2021.

“Networking and sharing of best practices is the only solution to solve the type of enormous challenges we are facing in our world. The global network is an original, simple and effective opportunity for this”.

Marco Albini, Chief of Quality Monitoring Office,
Istituto Clinico Humanitas

Beamtree and Potential^(x) Integration Rationale

- 1 *Accelerate growth in new global markets and adjacent sectors*
- 2 *Add value and market access for existing solutions and software*
- 3 *Reduce barriers to entry in ANZ market*
- 4 *Immediate market share, expertise and insight into public hospital sector*
- 5 *Grow our people, leadership, industry and technical expertise*
- 6 *Be cash flow positive and profitable*
- 7 *Integration of Potential(x) analytics and insights into other software and markets*

personal use only

Beamtree and Potential^(x) Integration Update

Scope of Post-Merger Integration (PMI) activity

To identify and action efficiencies in the organisational ways of working, value-creation, cost containment and avoidance, and organisation and operational alignment.

First 100 Days

The first 100 days of the PMI finished on track with nearly 60% of the overall integration initiatives identified for execution (pre and post first 100 days) completed. This includes:

- Rationalisation and consolidation of internal business-as-usual operational tools
- Aligned and unified methods of organisational ways-of-working
- Organisational structure and culture alignment
- Identification of synergies to enable early cross-sales opportunities to existing clients

New Executive Team



Tim Kelsey

Chief Executive Officer



Cheryl McCullagh

Chief Strategy Officer (Global)



Duane Attree

Chief Commercial and Development Officer



Cassandra Chen

Chief Financial Officer – Outgoing



Mark McLellan

Chief Financial Officer – Incoming

personal use only

personal use only

Financial Summary

1H FY22



1H FY22 – continued strong revenue growth


Comments

- Total Revenue growth of 91%, up to \$7.1m supported by 23.5% organic revenue growth YoY (exc. Acquisitions) due to new contract wins and strong performance in advisory projects. Potential(x) contributed \$2.5m revenue to the group for the half year.
- Annualised recurring revenue up +160% and increased to \$16.8m. Recurring revenue exceeds 85% of total group revenue driven by growth in SaaS subscription revenue and the contribution from acquisition in data analytics platform.
- Strong revenue growth in consultancy and advisory revenue of \$1m as successful conclusion of national clinical coding project in Saudi Arabia in Dec21
- Increase in Opex compared to pcp largely driven by \$2m cost contributed from acquisition and \$2.1m cost increase in headcount as the group invests in product, technology and direct sales capabilities
- Operational EBITDA loss of \$0.5m as investment made in 2021 calendar year to accelerate future growth.
- Increase in D&A relates to product development and acquired amortisation of IP


\$(,000)	1H FY22	1H FY21	YoY Var \$	YoYVar%
Subscription, License & Usage Revenue - recurring	3,546	3,053	493	16%
Data Analytics - recurring	2,310	-	2,310	-
Service Revenue - recurring	203	221	(18)	(8)%
Consultancy & other	1,075	455	620	136%
Revenue	7,134	3,729	3,405	91%
<i>Revenue (Organic)</i>	<i>4,604</i>	<i>3,729</i>	<i>875</i>	<i>24%</i>
Other income	398	276	122	31%
Total Revenue	7,532	4,005	3,526	47%
Total Operating cost	7,713	2,546	(5,167)	(67)%
Operational EBITDA (Non-GAAP)*	(181)	1,459	(1,641)	(112)%
% margin	(2)%	36%		
listing, one-off and acquisition expenses	737	745	8	1%
Options & performance rights	129	326	197	153%
D&A	1,323	371	(952)	(72)%
Loss before tax	(2,370)	17		

Revenue Composition

1H FY22 % of Recurring Revenue



Revenue Profile




Comments

- Recurring revenue exceeds 85% of total revenue, in line with 1H FY21 as group continues to focus on recurring revenue generation
- Revenue from core SaaS products grew by 11%
 - *RippleDown* growth 10%
 - *PICQ* growth 11%
 - *RISQ* growth 29%
- Revenue from direct customers has further increased to 94% of total revenue, from 89% in 1H FY21. it underpins strong sales and go to market capabilities

Annual Recurring Revenue Growth

Comments

- Annual Recurring Revenue (ARR) has increased at a CAGR of 72% since 1H FY20 on statutory basis.
- The acquisition of Potential(x) has substantially increased Beamtree's ARR through data analytics by adding \$9.2m as at the half year.
- Increase in recurring subscriptions and coding services due to new clients and contract wins in Australia and globally which drives 17% growth YoY. Key clients include Central Adelaide Local Health Network, Children's Health Queensland Hospital, Southern DHB New Zealand



Statutory Balance Sheet

Comments

- \$6.5m of net cash – position remains strong
- Debtors balance increased by \$3.1m compared to 30 June 2021. Debtor balance of Potential^(x) contributes \$1.8m to the total of which \$1.6m related to Health Roundtable and received post year end. The remaining of debtors balance relates to mainly the milestone payments from Saudi project which expect to receive in 2H
- Non current asset largely comprises of software intangibles, right-of-use asset from AASB16 and goodwill. Increase in intangible asset reflecting acquired assets through acquisitions and continued investment in product and innovation
- Increase in current liabilities are mainly driven by additional employee benefits as group headcount grows. Contract liabilities represents annual license and subscription invoiced to clients in advance and recognise as revenue over the following periods
- Increase in other-current liabilities are related to deferred shares from Potential(x) acquisition

\$(,000)	31 Dec 2021	30 June 2021
Assets		
Current assets		
Cash and cash equivalents	7,038	14,117
Trade & other receivables	5,219	2,132
Contracts asset	488	1,119
Total current assets	12,745	17,368
Non-current assets	51,596	29,686
Total Assets	64,341	47,055
Liabilities		
Total current liabilities	5,865	3,758
Total non-current liabilities	7,422	1,206
Total liabilities	13,287	4,964
Net Assets	51,054	42,091

Statutory Cashflow

Comments

Operating cashflow

- Net cash outflow is driven by timing in receiving \$1.9m (USD \$1.4m) from completion of Saudi project (expect to receive in 2H) and debtors balance of \$1.6m related to Health Round Table (received post half year-end).
- Increase in operating cost driven by headcount grew

Investing cashflow

- \$1.4m invested in research and product development
- \$2.6m reflecting net upfront cash consideration paid for acquisition of AINSOFF and Potential^(x)

Financing cashflow

- Net cashflow movement reflect proceeds from the exercise of options and lease payments.

\$(,000)	1H FY22
Receipts from customers (inclusive of GST)	6,644
Payments to suppliers and employees (inclusive of GST)	(8,866)
Other	24
Net cash from / (used in) operating activities	(2,198)
Payment for purchase of business, net of cash acquired	(2,653)
Payments for property, plant and equipment	(12)
Payments for intangibles	(2,214)
Net cash from / (used in) investing activities	(4,879)
Repayments of lease liabilities	(242)
Proceeds from issuing of share capital	240
Net cash from / (used in) financing activities	(2)
Net cash movement	(7,079)
Opening Cash Balance	14,117
Closing Cash Balance	7,038

Important Notice and Disclaimer

The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, 15 February 2022.

This presentation may contain statements that are, or may be deemed to be, forward looking statements. Such statements can generally be identified by the use of words such as “believe”, “estimate”, “plan”, “target”, “project”, “anticipate”, “expect”, “intend”, “likely”, “may”, “will”, “could” or “should” and similar expressions. Indications of strategy, plans, objectives, targets, goals, future events or intentions are also forward looking statements.

You should not place undue reliance on such forward-looking statements. Such forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BMT or any of its related entities which may cause actual results to differ materially from those expressed or implied in such statements.

No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation. Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.

The information in the presentation is given for informational purposes only, is in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with BMT’s other announcements to ASX. It is not intended to be relied upon as advice to current shareholders, investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation is made as to the accuracy, completeness or reliability of the presentation.

The views expressed in this presentation may contain information that has been derived from publicly available sources that have not been independently verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information. Market share information is based on management estimates except where explicitly identified.

To the maximum extent permitted by law, BMT and any person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation, any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

BMT is not obliged to, and does not represent that it will, update the presentation for future developments. All currency figures are in Australian dollars unless otherwise stated. Totals may not add up precisely due to rounding.

personal use only

